da Silva Jorge Santos
Known title: Chief Executive OfficerCIK: 0001920509
Associated companies
Transaction History
| MLTX | ▼ Sell | Open Market | 68,289 | $1.4M | 7/10/2026 | View on chart |
| MLTX | ▼ Sell | Open Market | 33,936 | $679K | 7/9/2026 | View on chart |
| MLTX | ▼ Sell | Open Market | 47,775 | $957K | 7/1/2026 | View on chart |
| MLTX | ▼ Sell | Open Market | 51,873 | $946K | 4/13/2026 | View on chart |
| MLTX | ▼ Sell | Open Market | 98,127 | $1.8M | 4/10/2026 | View on chart |
| MLTX | ▼ Sell | Other | 196,316 | — | 12/19/2025 | View on chart |
| MLTX | ▼ Sell | Other | 196,316 | — | 12/19/2025 | View on chart |
| MLTX | ▼ Sell | Open Market | 70,000 | $1.0M | 12/9/2025 | View on chart |
| MLTX | ▼ Sell | Open Market | 130,000 | $2.0M | 12/8/2025 | View on chart |
| MLTX | ▲ Buy | Grant | 95,763 | $0 | 2/27/2025 | View on chart |
| MLTX | ▼ Sell | Open Market | 4,740 | $265K | 2/29/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 56,065 | $3.1M | 2/28/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 62,810 | $3.5M | 2/27/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 1,125 | $62K | 2/21/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 20,000 | $1.1M | 2/20/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 20,000 | $1.2M | 2/16/2024 | View on chart |
| MLTX | ▼ Sell | Open Market | 20,000 | $1.2M | 2/15/2024 | View on chart |
| MLTX | ▼ Sell | Other | 3,027,483 | — | 10/1/2023 | View on chart |
| MLTX | ▼ Sell | Other | 140,071 | — | 10/1/2023 | View on chart |
| MLTX | ▼ Sell | Other | 140,071 | — | 10/1/2023 | View on chart |
| MLTX | ▼ Sell | Other | 3,027,483 | — | 10/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MLTX noted in psoriatic arthritis market landscape report
A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.
MLTX noted in psoriatic arthritis market landscape report. A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.